RTRamazan Gökmen Turan

Ramazan Gökmen Turan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ramazan Gökmen Turan has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Ilkay Bozdag-Turan

    Buelent Koektuerk, Murat Aksoy, Marc Horlitz, Ramazan Goekmen Turan, Department of Cardiology/Electrophysiology, Witten/Herdecke University, Krankenhaus Porz am Rhein, 58448 Cologne, Germany

    4 shared publications
  • C Hakan Turan

    Department of Internal Medicine, Division of Cardiology, University hospital Rostock, Ernst Heydemann Str 6, Rostock, 18055, Germany

    3 shared publications
  • Christoph A. Nienaber

    Department of Internal Medicine, Division of Cardiology, University Hospital Rostock

    3 shared publications
  • Henrik Schneider

    Department of Internal Medicine, Division of Cardiology, University Hospital Rostock

    3 shared publications
  • Henrik Schneider

    Department of Cardiology, Heart Center Rostock, Medizinische Klinik I, Universitätsklinikum Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany

    3 shared publications
  • Hueseyin Ince

    Department of Internal Medicine, Division of Cardiology; University Hospital Rostock; Germany

    3 shared publications

Latest Publications

  • Open Access

    Role of diabetes in heart rhythm disorders

    by Buelent Koektuerk, Murat Aksoy, Marc Horlitz, Ilkay Bozdag-Turan, Ramazan Goekmen Turan

    Role of diabetes in heart rhythm disorders


  • Open Access

    Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease

    by Ilkay Bozdag-Turan, R Goekmen Turan, Lylia Paranskaya, Nicole S Arsoy, C Hakan Turan, Ibrahim Akin, Stephan Kische, Jasmin Ortak, H Schneider, S Ludovicy, et al.

    Bone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease are impaired with respect to number and functional activity. However, the relation between the functional activity of BM-CPCs and the number of diseased coronary arteries is yet not known. We analyzed the influence of the number of diseased coronary arteries on the functional activity of BM-CPCs in peripheral blood (PB) in patients with ischemic heart disease (IHD).


  • Open Access

    Intra coronary freshly isolated bone marrow cells transplantation improve cardiac function in patients with ischemic heart disease

    by Ilkay Bozdag-Turan, R Goekmen Turan, Sophie Ludovicy, Ibrahim Akin, Stephan Kische, Henrik Schneider, Tim C Rehders, C Hakan Turan, Nicole S Arsoy, Tina Hermann, et al.

    Background: Autologous bone marrow cell transplantation (BMCs-Tx) is a promising novel option for treatment of cardiovascular disease. In this study we analyzed whether intracoronary autologous freshly isolated BMCs-Tx have beneficial effects on cardiac function in patients with ischemic heart disease (IHD). Results: In this prospective nonrandomized study we treated 12 patients with IHD by freshly isolated BMCs-Tx by use of point of care system and compared them with a representative 12 control group without cell therapy. Global ejection fraction (EF) and infarct size area were determined by left ventriculography. Intracoronary transplantation of autologous freshly isolated BMCs led to a significant reduction of infarct size (p < 0.001) and an increase of global EF (p = 0.003) as well as infarct wall movement velocity (p < 0.001) after 6 months follow-up compared to control group. In control group there were no significant differences of global EF, infarct size and infarct wall movement velocity between baseline and 6 months after coronary angiography. Furthermore, we found significant decrease in New York Heart Association (NYHA) as well as significant decrease of B-type natriuretic peptide (BNP) level 6 months after intracoronary cell therapy (p < 0.001), whereas there were no significant differences in control group 6 months after coronary angiography. Conclusions: These results demonstrate that intracoronary transplantation of autologous freshly isolated BMCs by use of point of care system is safe and may lead to improvement of cardiac function in patients with IHD. Trial registration: Registration number: ISRCTN54510226


  • Open Access

    Enhanced mobilization of the bone marrow–derived circulating progenitor cells by intracoronary freshly isolated bone marrow cells transplantation in patients with acute myocardial infarction

    by R. G. Turan, I. Bozdag‐T, C. H. Turan, J. Ortak, I. Akin, S. Kische, H. Schneider, M. Rauchhaus, T. C. Rehders, T. Kleinfeldt, et al.

    Autologous bone marrow cell transplantation (BMCs‐Tx) is a promising novel option for treatment of cardiovascular disease. We analysed in a randomized controlled study the influence of the intracoronary autologous freshly isolated BMCs‐Tx on the mobilization of bone marrow–derived circulating progenitor cells (BM‐CPCs) in patients with acute myocardial infarction (AMI). Sixty‐two patients with AMI were randomized to either freshly isolated BMCs‐Tx or to a control group without cell therapy. Peripheral blood (PB) concentrations of CD34/45+‐ and CD133/45+‐circulating progenitor cells were measured by flow cytometry in 42 AMI patients with cell therapy as well as in 20 AMI patients without cell therapy as a control group on days 1, 3, 5, 7, 8 and 3, 6 as well as 12 months after AMI. Global ejection fraction (EF) and the size of infarct area were determined by left ventriculography. We observed in patients with freshly isolated BMCs‐Tx at 3 and 12 months follow up a significant reduction of infarct size and increase of global EF as well as infarct wall movement velocity. The mobilization of CD34/45+ and CD133/45+ BM‐CPCs significantly increased with a peak on day 7 as compared to baseline after AMI in both groups (CD34/45+: P < 0.001, CD133/45+: P < 0.001). Moreover, this significant mobilization of BM‐CPCs existed 3, 6 and 12 months after cell therapy compared to day 1 after AMI. In control group, there were no significant differences of CD34/45+ and CD133/45+ BM‐CPCs mobilization between day 1 and 3, 6 and 12 months after AMI. Intracoronary transplantation of autologous freshly isolated BMCs by use of point of care system in patients with AMI may enhance and prolong the mobilization of CD34/45+ and CD133/45+ BM‐CPCs in PB and this might increase the regenerative potency after AMI.


  • Open Access

    Improvement of Cardiac Function by Intracoronary Freshly Isolated Bone Marrow Cells Transplantation in Patients With Acute Myocardial Infarction

    by Ramazan Gökmen Turan, Ilkay Bozdag-Turan, Jasmin Ortak, Ibrahim Akin, Stephan Kische, Henrik Schneider, Tim Christopher Rehders, Cem Hakan Turan, Mathias Rauchhaus, Tilo Kleinfeldt, et al.

    Background: We analyzed in the present study the influence of intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs-Tx) on cardiac function in patients with acute myocardial infarction (AMI). Methods and Results: The 32 patients with AMI were enrolled in this prospective nonrandomized study to either freshly isolated BMC-Tx or to a control group without cell therapy. Global left ventricular ejection fraction (LVEF) and the size of infarct area were determined by left ventriculography. We observed in patients with autologous freshly isolated BMCs-Tx at 6 months follow up a significant reduction of infarct size as compared to control group. Moreover, we found a significant increase of LVEF as well as infarct wall movement velocity at 6 months follow up in cell therapy group as compared to control group. In the control group there was no significant difference of LVEF, infarct size and infarct wall movement velocity between baseline and 6 months after AMI. Conclusions: These results demonstrate for the first time that intracoronary transplantation of autologous freshly isolated BMCs by use of a point of care system is safe, and may lead to improvement of cardiac function in patients with AMI. (Circ J 2011; 75: 683-691)


  • Impaired Mobilization of CD133+ Bone Marrow-Derived Circulating Progenitor Cells With an Increased Number of Diseased Coronary Arteries in Ischemic Heart Disease Patients With Diabetes

    by R. Goekmen Turan, C. Hakan Turan, Ilkay Bozdag-Turan, Jasmin Ortak, Ibrahim Akin, Stephan Kische, Henrik Schneider, Tilo Kleinfeldt, Tim C. Rehders, Mathias Rauchhaus, et al.

    Background: The influence of the number of diseased coronary arteries on the mobilization of CD133/45+ bone marrow-derived circulating progenitor cells (BM-CPCs) in peripheral blood (PB) in patients with ischemic heart disease (IHD) was analyzed. Methods and Results: Mobilization of CD133/45+ BM-CPCs by flow cytometry was measured in 120 patients with coronary 1 vessel (IHD1, n=40), coronary 2 vessel (IHD2, n=40), and coronary 3 vessel disease (IHD3, n=40), and in a control group (n=40). The mobilization of CD133/45+ BM-CPCs was significantly reduced in patients with IHD compared to the control group (P+ BM-CPCs was impaired in patients with IHD3 compared to IHD1 (P+ BM-CPCs between the patients with IHD2 and IHD1 (P=0.35). Moreover, we found significantly reduced CD133/45+ cell mobilization in patients with a high SYNTAX-Score (SS) compared to a low SS (P1c and the mobilization of CD133/45+ BM-CPCs (P=0.001, r=-0.6). Conclusions: The mobilization of CD133/45+ BM-CPCs in PB is impaired in patients with IHD. This impairment might augment with increased number of diseased coronary arteries. Moreover, mobilization of CD133/45+ BM-CPCs in ischemic tissue is further impaired by diabetes in patients with IHD. (Circ J 2011; 75: 2635-2641)


  • Open Access

    Relation between the frequency of CD34+ bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes

    by Ilkay Bozdag-Turan, R Goekmen Turan, C Hakan Turan, Sophie Ludovicy, Ibrahim Akin, Stephan Kische, Nicole S Arsoy, Henrik Schneider, Jasmin Ortak, Tim Rehders, et al.

    Bone marrow-derived circulating progenitor cells (BM-CPCs) in patients with coronary heart disease are impaired with respect to number and mobilization. However, it is unknown whether the mobilization of BM-CPCs depends on the number of diseased coronary arteries. Therefore, in our study, we analysed the correlation between the diseased coronary arteries and the frequency of CD34/45+ BM-CPCs in peripheral blood (PB) in patients with ischemic heart disease (IHD).


  • Open Access

    Improved Mobilization of the CD34 + and CD133 + Bone Marrow-Derived Circulating Progenitor Cells by Freshly Isolated Intracoronary Bone Marrow Cell Transplantation in Patients with Ischemic Heart Disease

    by Ramazan Gökmen Turan, Ilkay Bozdag-Turan, Jasmin Ortak, Ibrahim Akin, Stephan Kische, Henrik Schneider, Cem Hakan Turan, Tim Christopher Rehders, Mathias Rauchhaus, Tilo Kleinfeldt, et al.

    Cell therapy is a promising novel option for treatment of cardiovascular disease. Because the role of bone marrow-derived circulating progenitor cells (BM-CPCs) after cell therapy is less clear, we analyzed in this randomized, controlled study the influence of intracoronary autologous freshly isolated bone marrow cell transplantation (BMC-Tx) by using a point-of-care system on cardiac function and on the mobilization of BM-CPCs in patients with ischemic heart disease (IHD). Fifty-six patients with IHD were randomized to either receive freshly isolated BMC-Tx or a control group that did not receive cell therapy. Peripheral blood concentrations of CD34/45 + and CD133/45 + CPCs were measured by flow cytometry pre-, immediately post-, and at 3, 6, and 12 months postprocedure in both groups. Global ejection fraction and the size of infarct area were determined by left ventriculography. We observed in patients with IHD after intracoronary transplantation of autologous freshly isolated BMCs-Tx at 3 and 12 months follow-up a significant reduction of the size of infarct area and increase of global ejection fraction as well as infarct wall movement velocity. The mobilization of CD34/45 + and CD133/45 + BM-CPCs significantly increased at 3, 6, and 12 months after cell therapy when compared with baseline in patients with IHD, although no significant changes were observed between pre- and immediately postintracoronary cell therapy administration. In the control group without cell therapy, there was no significant difference of CD34/45 + and CD133/45 + BM-CPCs mobilization between pre- and at 3, 6, and 12 months postcoronary angiography. Intracoronary transplantation of autologous freshly isolated BMCs by using a point-of-care system in patients with IHD may enhance and prolong the mobilization of CD34/45 + and CD133/45 + BM-CPCs in peripheral blood and this might increase the regenerative potency in IHD.


  • Open Access

    Improved Functional Activity of Bone Marrow Derived Circulating Progenitor Cells After Intra Coronary Freshly Isolated Bone Marrow Cells Transplantation in Patients with Ischemic Heart Disease

    by R. Goekmen Turan, I. Bozdag-T, J. Ortak, S. Kische, I. Akin, H. Schneider, C. H. Turan, T. C. Rehders, M. Rauchhaus, T. Kleinfeldt, et al.

    Objectives There is growing evidence that intracoronary autologous bone marrow cells transplantation (BMCs-Tx) in patients with chronic myocardial infarction beneficially affects postinfarction remodelling. In this randomized controlled study we analyzed the influence of intracoronary autologous freshly isolated bone marrow cells transplantation by use of point of care system on cardiac function and on the functional activity of bone marrow derived circulating progenitor cells (BM-CPCs) in patients with ischemic heart disease (IHD). Methods 56 patients with IHD were randomized to either received freshly isolated BMC-Tx or a control group that did not receive cell therapy. The functional activity of BM-CPCs in peripheral blood (PB) was measured by migration assay and colony forming unit assay pre- and 3, 6 as well as 12 months after procedure. Global ejection fraction (EF) and infarct size area were determined by left ventriculography. Results Intracoronary transplantation of autologous freshly isolated BMCs led to a significant reduction of infarct size and an increase of global EF as well as infarct wall movement velocity after 3 and 12 months follow-up compared to control group. The colony-forming capacity of BM-CPCs significantly increased 3, 6 and 12 months after cell therapy compared to pre BMCs-Tx and control group (CFU-E: p < 0.001, CFU-GM: p < 0.001). Likewise, we found significant increase of migratory response to stromal cell-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) after cell therapy compared to pre BMCs-Tx (SDF-1: p < 0.001, VEGF: p < 0.001) and to control (SDF-1: p < 0.001, VEGF: p < 0.001). There was no significant difference of migratory- and colony forming capacity between pre- and 3, 6, 12 months after coronary angiography in control group without cell therapy. Conclusions Intracoronary transplantation of autologous freshly isolated BMCs by use of point of care system may lead to improvement of BM-CPCs functional activity in peripheral blood, which might increase the regenerative potency in patients with IHD.